IRWD Ironwood Pharmaceuticals
- 6.690
- 0.0000.00%
Ironwood Pharmaceuticals News
US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
Ironwood Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Ironwood Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Ironwood Pharmaceuticals Price Target Cut to $14.00/Share From $18.00 by Craig-Hallum
Ironwood Pharmaceuticals Price Target Cut to $14.00/Share From $18.00 by Craig-Hallum
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy and lowers the price target from $18 to $14.
Ironwood Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 101.44% Craig-Hallum $18 → $14 Maintains Buy 03/01/2024 101.44% Wells Fargo $20 → $14 Maintains
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Ironwood Pharmaceuticals, Inc. IRWD reported an adjusted loss of 2 cents per share for first-quarter 2024 in contrast to the Zacks Consensus Estimate of earnings of 18 cents per share.
Ironwood Pharmaceuticals: A Buy Rating Amidst Strong Product Positioning and Promising Clinical Data
Ironwood Pharmaceuticals | 10-Q: Quarterly report
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results.Duolingo reported quarterly earnings of 57 cents per share whic
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading
Health care stocks were rising Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.8%. The iShares Biotechnology ETF (IBB) rose 0.7%. In
Sector Update: Health Care
Health care stocks were gaining Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) were both climbing 0.7%. The iShares Biotechnology ETF (IBB) rose
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut
Ironwood Pharmaceuticals (IRWD) shares were down more than 22% in recent early Thursday trading after the company reported a Q1 non-GAAP loss of $0.02, swinging from earnings of $0.25 a year earlier.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Ironwood Pharmaceuticals (IRWD.US): The 2024 Q1 financial report achieved revenue of US$74.877 million, with a previous value of US$104.1 million and an expected value of US$106.3 million; earnings per share were -0.02 US dollars, the previous value was $
Ironwood Pharmaceuticals (IRWD.US): The 2024 Q1 financial report achieved revenue of US$74.877 million, with a previous value of US$104.1 million and an expected value of US$106.3 million; earnings per share were -0.02 US dollars, the previous value was $0.25, and the expected value was $0.20.
Ironwood Pharmaceuticals Q1 2024 Adj EPS $(0.02) Misses $0.19 Estimate, Sales $74.877M Miss $105.804M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.19 by 110.53 percent. This is a 108 percent decrease over earnin
GUIDANCE: (IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M
07:12 AM EDT, 05/09/2024 (MT Newswires) -- GUIDANCE: (IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M
07:12 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M
Ironwood Pharmaceuticals Cuts FY24 View To Rev $405M-$425M >IRWD
Ironwood Pharmaceuticals Cuts FY24 View To Rev $405M-$425M >IRWD
Ironwood Pharmaceuticals Revises FY24 Guidance Due to LINZESS Gross-To-Net Change in Estimate >IRWD
Ironwood Pharmaceuticals Revises FY24 Guidance Due to LINZESS Gross-To-Net Change in Estimate >IRWD
Ironwood Pharmaceuticals 1Q Loss/Shr 3c >IRWD
Ironwood Pharmaceuticals 1Q Loss/Shr 3c >IRWD
Analysis
Price Target
No Data
